atrial fibrillation Archives
Genes and age studied as markers for higher death rate in those with atrial fibrillation
Jun. 8, 2022—Younger patients with atrial fibrillation who had rare genetic variants associated with inherited cardiomyopathy and arrythmia syndromes were associated with a significantly higher rate of death than those without the variants, a Vanderbilt-led study has shown.
Peptides promote AFib arrhythmia
Apr. 11, 2022—Peptide oligomers have detrimental metabolic effects and cause pro-arrhythmic electrophysiological changes in heart atria, suggesting they may contribute to atrial fibrillation.
Study finds apixaban (Eliquis) is preferable to rivaroxaban (Xarelto) for stroke prevention, reduced bleeding complications
Dec. 21, 2021— by Jill Clendening There is strong evidence that the medication apixaban (Eliquis) is preferable to rivaroxaban (Xarelto) for stroke prevention in patients with atrial fibrillation (AF), with both reduced rates of severe bleeding complications as well as strokes, according to study published Dec. 21 in JAMA. An estimated 3 million to 6 million persons...
Study finds genetic testing useful for young AFib patients
Oct. 7, 2021—Vanderbilt research shows that genetic testing in patients with early-onset atrial fibrillation can identify variants associated with more serious cardiomyopathy and arrhythmia syndromes that may otherwise remain undiagnosed.
VHVI offers latest therapies to treat atrial fibrillation
Sep. 9, 2021—Vanderbilt Heart and Vascular Institute continues to offer the latest in therapies to treat atrial fibrillation (AF or AFib), the most common cardiac arrhythmia.
Device to treat AFib may eliminate need for blood thinners
Mar. 18, 2021—Vanderbilt University Medical Center is participating in a trial for a device that could revolutionize the way patients are treated for atrial fibrillation (AF or AFib.)
Genotype looms large in risk for post-op arrhythmia
Mar. 11, 2021—Postoperative atrial fibrillation (PoAF), a form of arrhythmia, complicates 20-40% of cardiac surgical procedures and 10–20% of non-cardiac thoracic operations, cropping up two to four days after surgery to pose risk of stroke, heart attack, mortality, longer hospital stays and greater cost.
Minimally invasive treatment option for AFib studied
Oct. 22, 2020—A minimally invasive procedure that combines ligation of the left atrial appendage (LAA) with hybrid epicardial-endocardial ablation is a feasible, safe and effective method of treating patients with longstanding atrial fibrillation (AF or AFib), according to a new Vanderbilt-led study.
Device helps heart patients ditch blood thinners
Feb. 7, 2019—For the first time in 27 years, Jerry Flowers is looking at life without using blood thinners, thanks to a small device that was implanted in his heart in a clinical trial at Vanderbilt Heart and Vascular Institute (VHVI).
Research bolsters thyroid function, atrial fibrillation link
Jan. 31, 2019—A study by researchers at Vanderbilt University Medical Center has strengthened the link between thyroid function and atrial fibrillation (AF), an irregular heart rhythm that increases the risk of stroke and other heart-related complications.
VUMC joins research network to fight atrial fibrillation
Jun. 14, 2018—Vanderbilt University Medical Center (VUMC) has been selected by the American Heart Association (AHA) to participate in a six-member research network to advance treatment and prevention of atrial fibrillation (AFib), an irregular heart rate that increases the risk of stroke and other heart-related complications.
Multiple options help atrial fibrillation patients
Feb. 22, 2018—Since launching its program offering patients with non-valvular atrial fibrillation (AF) an alternative treatment to reduce their risk of stroke and avoiding long-term use of blood thinners, the Vanderbilt Heart and Vascular Institute (VHVI) has consistently ranked among the top centers in the country for the implantation of left atrial appendage closure (LAAC) devices.
